Researchers from Clinical Hospital Center Rijeka Describe Findings in Multiple Myeloma (Bortezomib-based Regimen Affects Cognitive Functions In Multiple Myeloma Patients Through the Vegf Pathway - Hypothesis That Connects Different Knowledge...).

Předmět:	BLOOD protein disorders BLOOD diseases LYMPHATIC diseases HEMORRHAGIC diseases LYMPHOPROLIFERATIVE disorders
Zdroj:	Hematology Week; 12/10/2024, p964-964, 1p
Abstrakt:	Researchers from Clinical Hospital Center Rijeka in Croatia have explored the impact of bortezomib-based treatment on cognitive functions in multiple myeloma patients. They hypothesize that bortezomib may impair cognition by reducing levels of the neuroprotective cytokine vascular endothelial growth factor (VEGF). This study suggests that VEGF could potentially serve as a biomarker for cognitive dysfunction, enabling early detection and appropriate treatment selection for patients with multiple myeloma. The research aims to pave the way for future studies to improve the management of multiple myeloma and enhance patients' quality of life. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu